Prognostic Significance of Cyclooxygenase-2(COX-2) Expression in Primary, Resected Non-Small Cell Lung Cancer

원발성 비소세포폐암조직에서 Cyclooxygenase-2 발현의 예후인자로서의 의의

  • Kim, Hak Ryul (Department of Internal Medicine, Wonkwang University College of Medicine) ;
  • Yang, Sei Hoon (Department of Internal Medicine, Wonkwang University College of Medicine) ;
  • Jeong, Eun Taik (Department of Internal Medicine, Wonkwang University College of Medicine)
  • 김학렬 (원광대학교 의과대학 내과학교실) ;
  • 양세훈 (원광대학교 의과대학 내과학교실) ;
  • 정은택 (원광대학교 의과대학 내과학교실)
  • Published : 2004.02.28


Background : Cyclooxygenase is the main target enzyme for the nonsteroidal anti inflammatory drugs (NSAIDs) that have been shown to suppress carcinogenesis in both experimental models and epidemiological studies. COX-2 plays an important role in solid tumor growth, invasiveness and angiogenesis, through, in part, the synthesis of prostaglandins, such as prostaglandin E2 (PGE2). In this study, the prognostic significance of an increase in COX-2 expression in lung cancer samples was evaluated. Material and Methods : The expression of COX-2, by immunohistochemistry, was studied in paraffin-embedded tumor blocks obtained from 84 patients(male 67, female 17, with a mean age of 63, ranging from 34 to 84 years) who had undergone surgery at Wonkwang University Hospital, between 1997 and 2002. For the evaluation of the relationships between COX-2 expression, and the clinical stage, metastasis to lymph nodes and survival, those cases showing the respective antigen expression in >10% of the tumor cells were considered positive. Result : Of the 84 patients, 61 (73%) exhibited more than 10% COX-2 immunoreactivities in the tumor and normal cells, whereas the remaining 23 showed no increase in the expression of COX-2. There was no significant relationship between the increased expression of COX-2 and the disease stage(p=0.1002) or cell type(p=0.152). The median survival was longer for the patients with a negative, compared to positive, COX-2 expression(36 compared to 24 months, p<0.05). The two year-survival rate was also higher in the patients with a negative COX-2 expression (78%) than those with a positive expression (47%, Kaplan-Meier, Log Rank, p < 0.05). Conclusion : The median survival was longer in the patients with a negative, compared to positive, COX-2 expression was longer than those with positive COX-2, having undergone complete resection due to primary non-small cell lung cancer.


Supported by : 원광대학교


  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA J Clin 1998;48:6-29
  2. Garfinkel L, Stellman SD. Smoking and lung cancer in women: findings in a prospective study. Cancer Res 1998;48:6951-5
  3. The Alpha-Tocopherol, B. C. C. P. S. G. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35
  4. Omenn GS. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (see comments). N Engl J Med 1996;334:1150-5
  5. Tsuji M. Dubois R. Alterations in cellularadhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995;83:493-501
  6. Giardiello FM, Offerhans GJA, DuBois RN. The role of non steroidal antiinflammatory drugs in colorectal cancer prevention. Eur J Cancer 1995;31A:1071-6
  7. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al.Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-4
  8. Dubois RN. Smalley WE. Cyclooxygenase, NSAIDs and colorectal cancer. J Gastroenterol 1996;31:898-906
  9. Steele VE, Moon RC, Luber RA, Grubbs CJ, Reddy BS, Wargovich M, et al. Preclinical efficacy evaluation of potential chemopreventive agent in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl 1994;20:32-54
  10. Lupulesco A. Prostaglandins, their inhibitors and cancer. Prostoglandins Leukot Essent Fatty Acids 1996;54:83-94
  11. Castonguay A, Rioux N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis 1997;18:491-6
  12. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188
  13. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16
  14. Ferrandina L, Lauriola MG, Distefano GF, Zannoni M, Gessi F, Legge N, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002;20:973-81
  15. John GE, Stephen PF, Simon MP, Keith RA, Rosemary AW, David AW, et al. Cycloo-xygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002;8:1857-62
  16. Hiroyuki A, Yatabe Y, Hinda T, Kuroishi T, Kozaki K, Nakamura S, et al. prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5
  17. Fadlo RK, Wu H, Lee jj, Kemp BL, Lotan R, Lippman SM, et al. cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-67
  18. Hast$\ddot{u}$rk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS. Expression of cyclo-oxygenase-1 and cyclooxygenase-2 in bronchial epithelium and non small cell lung carcinoma. cancer 2002;15:94(4):1023-31
  19. Terano A, Ota S, Mach T, Hiraishi H, Stachura J, Tarnawski A, ET AL. Prostaglandin protects against taurocholate-induced damage to rat gastric mucosal cell culture. Gastroenterology 1987;92:669-77
  20. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, et al. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999;187:295-301
  21. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996;56:5125-7
  22. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K, Cyclo-oxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204
  23. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001
  24. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723-9
  25. Jiro O, Hirofumi Y, Yoshiyuki F, Tsujie M, Kondo M, Noura S, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-24
  26. Awad S, Yamamoto H, Doki Y, Jiro O, Kondo M, Fujiwara Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000;6:1229-38
  27. Chae SW, Sohn JH, Shin HS, Park YE. Expression of cyclooxygenase-2 protein in gastric carcinogenesis. Cancer Res and Treat 2002;34:252-7
  28. Ari R, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognosticsignificance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62. 2002;1:632-5
  29. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, NaKamura S, et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4
  30. Leander E, Christian D, Monika E. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604-10